METIS

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

Retrieved on: 
星期三, 五月 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Pfizer, Investment, NMPA, Pancreatic cancer, Schizophrenia, ASCO, HKT, Ovarian cancer, AstraZeneca, ELCC, Lung cancer, METIS, Food, CER, Genmab, Roche, GIST, CABP, Psoriasis, BLA, Bristol Myers Squibb, NSCLC, Psychosis, HKEX, NRDL, Safety, SCLC, Research and development, ABSSSI, Marketing, BMS, Clinical trial, Bronchopneumonia, GMG, TED, KarXT, Nivolumab, NDA, Stromal cell, MAA, Carcinoma, Administration, ADS, Patient, Society, Annual general meeting, Sanofi, Growth, Pharmaceutical industry

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.
  • “Our first quarter results demonstrate strong commercial execution and pipeline progress across our potential first- and best-in-class product portfolio,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab.
  • In March 2024, Zai Lab presented findings from preclinical studies highlighting the therapeutic potential of ZL-1310 at the European Lung Cancer Congress (ELCC) 2024.
  • Zai Lab to initiate a global Phase 2 study in mild-to-moderate chronic plaque psoriasis in the second quarter of 2024.

Novocure Reports First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 2, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, METIS, Congress, Cancer, Paclitaxel, EDT, Investment, Temozolomide, Food, Survival, Gynaecology, Immunotherapy, Lung cancer, Partnership, GBM, Webcast, Glioblastoma, Disclosure, IND, Prescription, ASCO, Regulation Fair Disclosure, Patient, Brain, Society, Loss, Regulation, PLD, Marketing, Clinical trial, NSCLC, PMA, Investigational New Drug, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.
  • Research, development, and clinical studies expenses for the quarter were $51.6 million, a decrease of 14% from the same period in 2023.
  • Sales and marketing expenses for the quarter were $55.2 million, an increase of 8% compared to the same period in 2023.
  • Novocure will host a conference call and webcast to discuss first quarter 2024 financial results at 8:00 a.m. EDT today, Thursday, May 2, 2024.

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Retrieved on: 
星期三, 四月 24, 2024
Oncology, Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, METIS, Efficacy, Safety, Patient, Deep learning, International, TIGER, Abstract, Survival, Metastasis, Lung cancer, MD, Baptist Health South Florida, Glioblastoma, ASCO, Radiation therapy, Pembrolizumab, Treatment, Brain, Society, Platinum, CDT, Clinical trial, Annual general meeting, Baptist Health, NSCLC, Medical imaging

METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NSCLC.

Key Points: 
  • METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NSCLC.
  • “We are honored to present the results of the METIS clinical trial as a late-breaking abstract this year at ASCO, the largest global oncology conference,” said Asaf Danziger, Novocure’s Chief Executive Officer.
  • “Patients with brain metastases from non-small cell lung cancer need more treatment options.
  • The METIS trial demonstrated that TTFields Therapy delayed intracranial progression while preserving neurological function, which is critical for these underserved patients.

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Retrieved on: 
星期三, 三月 27, 2024
Neurology, Radiology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, EST, Baptist Health, METIS, Baptist Health South Florida, NSCLC, Webcast, Patient, Radiosurgery, Brain, Regulation, SRS, Disclosure, MD, Quality of life, Lung cancer, Congress, Regulation Fair Disclosure, Clinical trial, Cognition, Radiation therapy, Medical imaging

Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis (n=298; hazard ratio=0.67; P=0.016).

Key Points: 
  • Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis (n=298; hazard ratio=0.67; P=0.016).
  • Median TTFields therapy treatment duration was 16 weeks and median usage was 67%.
  • Consistent with previous studies, TTFields therapy was well-tolerated with sustained quality of life and neurocognitive function.
  • Certain secondary endpoints showed positive trends in favor of treatment with TTFields therapy, including time to distant progression and quality of life.

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Retrieved on: 
星期三, 三月 27, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Quality of life, Lung cancer, Patient, Clinical trial, METIS, NSCLC, SRS, Medical imaging

Median TTFields therapy treatment duration was 16 weeks and median usage was 67%.

Key Points: 
  • Median TTFields therapy treatment duration was 16 weeks and median usage was 67%.
  • Certain secondary endpoints showed positive trends in favor of treatment with TTFields therapy, including time to distant progression and quality of life.
  • Novocure also intends to publish these findings in a peer-reviewed scientific journal and share them at an upcoming scientific congress.
  • Zai Lab contributed to the METIS trial and achieved treatment of the first patient in Greater China in May 2021.

Flash News: OKX to Support Ethereum Dencun Mainnet Upgrade

Retrieved on: 
星期三, 三月 13, 2024
METIS, The Surge, Merge, OKX, ARB, MXC, ETH, MATIC, Data management, Cryptocurrency

OKX will be supporting the forthcoming Ethereum network's Dencun mainnet upgrade.

Key Points: 
  • OKX will be supporting the forthcoming Ethereum network's Dencun mainnet upgrade.
  • OKX assures that trading of the mentioned tokens and tokens belonging to their networks will not be affected during this network upgrade.
  • As a long-awaited part of "The Surge" in Ethereum's roadmap, the Ethereum Dencun upgrade tackles the network's scalability challenges.
  • Like the Merge and Ethereum Shanghai upgrades that came before, the Dencun upgrade introduces various EIPs, with EIP-4844 being the most notable.

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
星期二, 二月 27, 2024
Oncology, Mental Health, Health, Infectious Diseases, Neurology, Pharmaceutical, Biotechnology, NSCLC, TED, Blood pressure, Cervical cancer, Psoriasis, Cetuximab, Infection, New Drug Application, SCLC, MAA, National Medical Products Administration, PMA, CIDP, NTRK, FDA, Nivolumab, Food, GEJ, Shanda, Schizophrenia, PDUFA, CRC, Bristol Myers Squibb, BMS, ADP, Safety, Mirati, TPS, Disease, HKT, Patient, Clinical trial, METIS, Fusion, Pancreatic cancer, NDA, NMPA, Pharmaceutical industry

The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.

Key Points: 
  • The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.
  • Zai Lab has joined the global Phase 3 FORTITUDE-102 study of bemarituzumab in combination with nivolumab and chemotherapy in first-line gastric or GEJ cancer in Greater China.
  • Zai Lab to submit an sBLA to the NMPA for efgartigimod SC in CIDP in the first half of 2024.
  • Zai Lab to complete patient enrollment in the China bridging study in schizophrenia in the fourth quarter of 2024.

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
星期四, 二月 22, 2024
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Glioblastoma, NSCLC, Regulation, TRIDENT, PMA, Investment, Marketing, FDA, Partnership, Food, File, EST, Growth, Clinical trial, Loss, Alternating electric field therapy, Disclosure, GBM, Prescription, European, Lung cancer, Regulation Fair Disclosure, Webcast, Patient, METIS, Survival, Temozolomide, Cancer, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023.
  • “In 2023, we reached many milestones in our commercial, clinical and product development programs,” said Asaf Danziger, Novocure’s Chief Executive Officer.
  • Operational updates for the fourth quarter ended December 31, 2023:
    1,564 prescriptions were received in the quarter, an increase of 14% year-over-year.
  • Novocure will host a conference call and webcast to discuss fourth quarter and full year 2023 financial results at 8:00 a.m. EST today, Thursday, February 22, 2024.

Flash News: OKX DEX Aggregator Now Supports Metis, a Layer 2 Scaling Solution for Ethereum

Retrieved on: 
星期日, 二月 25, 2024
METIS, EVM, Web3, OKX, DEX, Cryptocurrency

OKX DEX Aggregator Now Supports Metis, a Layer 2 Scaling Solution for Ethereum

Key Points: 
  • OKX DEX Aggregator Now Supports Metis, a Layer 2 Scaling Solution for Ethereum
    OKX today announced that its DEX aggregator now supports the Metis network.
  • This integration allows users swap tokens and conduct cross-chain transactions on the Metis network through OKX DEX.
  • By enabling on-chain swaps and cross-chain transactions on Metis Network directly through OKX DEX, user convenience is greatly enhanced.
  • Metis is a Layer 2 scaling solution for Ethereum, providing a more efficient and scalable platform for DApps and transactions.

Flash News: OKX DEX Aggregator Now Supports Metis, a Layer 2 Scaling Solution for Ethereum

Retrieved on: 
星期日, 二月 25, 2024
METIS, EVM, Web3, OKX, DEX, Cryptocurrency

OKX DEX Aggregator Now Supports Metis, a Layer 2 Scaling Solution for Ethereum

Key Points: 
  • OKX DEX Aggregator Now Supports Metis, a Layer 2 Scaling Solution for Ethereum
    OKX today announced that its DEX aggregator now supports the Metis network.
  • This integration allows users swap tokens and conduct cross-chain transactions on the Metis network through OKX DEX.
  • By enabling on-chain swaps and cross-chain transactions on Metis Network directly through OKX DEX, user convenience is greatly enhanced.
  • Metis is a Layer 2 scaling solution for Ethereum, providing a more efficient and scalable platform for DApps and transactions.